File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Network-based drug repurposing for the treatment of COVID-19 patients in different clinical stages

TitleNetwork-based drug repurposing for the treatment of COVID-19 patients in different clinical stages
Authors
KeywordsCOVID-19
Drug repurposing
Network biology
Network pharmacology
Issue Date23-Feb-2023
PublisherElsevier
Citation
Heliyon, 2023, v. 9, n. 3 How to Cite?
Abstract

In the severe acute respiratory coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to develop effective treatments. Through a network-based drug repurposing approach, several effective drug candidates are identified for treating COVID-19 patients in different clinical stages. The proposed approach takes advantage of computational prediction methods by integrating publicly available clinical transcriptome and experimental data. We identify 51 drugs that regulate proteins interacted with SARS-CoV-2 protein through biological pathways against COVID-19, some of which have been experimented in clinical trials. Among the repurposed drug candidates, lovastatin leads to differential gene expression in clinical transcriptome for mild COVID-19 patients, and estradiol cypionate mainly regulates hormone-related biological functions to treat severe COVID-19 patients. Multi-target mechanisms of drug candidates are also explored. Erlotinib targets the viral protein interacted with cytokine and cytokine receptors to affect SARS-CoV-2 attachment and invasion. Lovastatin and testosterone block the angiotensin system to suppress the SARS-CoV-2 infection. In summary, our study has identified effective drug candidates against COVID-19 for patients in different clinical stages and provides comprehensive understanding of potential drug mechanisms.


Persistent Identifierhttp://hdl.handle.net/10722/331866
ISSN
2023 Impact Factor: 3.4
2023 SCImago Journal Rankings: 0.617
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWang, Xin-
dc.contributor.authorWang, Han-
dc.contributor.authorYin, Guosheng-
dc.contributor.authorZhang, Yan Dora-
dc.date.accessioned2023-09-28T04:59:13Z-
dc.date.available2023-09-28T04:59:13Z-
dc.date.issued2023-02-23-
dc.identifier.citationHeliyon, 2023, v. 9, n. 3-
dc.identifier.issn2405-8440-
dc.identifier.urihttp://hdl.handle.net/10722/331866-
dc.description.abstract<p>In the severe acute respiratory coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to develop effective treatments. Through a network-based drug repurposing approach, several effective drug candidates are identified for treating COVID-19 patients in different clinical stages. The proposed approach takes advantage of computational prediction methods by integrating publicly available clinical transcriptome and experimental data. We identify 51 drugs that regulate proteins interacted with SARS-CoV-2 protein through biological pathways against COVID-19, some of which have been experimented in clinical trials. Among the repurposed drug candidates, lovastatin leads to differential gene expression in clinical transcriptome for mild COVID-19 patients, and estradiol cypionate mainly regulates hormone-related biological functions to treat severe COVID-19 patients. Multi-target mechanisms of drug candidates are also explored. Erlotinib targets the viral protein interacted with cytokine and cytokine receptors to affect SARS-CoV-2 attachment and invasion. Lovastatin and testosterone block the angiotensin system to suppress the SARS-CoV-2 infection. In summary, our study has identified effective drug candidates against COVID-19 for patients in different clinical stages and provides comprehensive understanding of potential drug mechanisms.<br></p>-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofHeliyon-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectCOVID-19-
dc.subjectDrug repurposing-
dc.subjectNetwork biology-
dc.subjectNetwork pharmacology-
dc.titleNetwork-based drug repurposing for the treatment of COVID-19 patients in different clinical stages-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1016/j.heliyon.2023.e14059-
dc.identifier.scopuseid_2-s2.0-85149408079-
dc.identifier.volume9-
dc.identifier.issue3-
dc.identifier.eissn2405-8440-
dc.identifier.isiWOS:000969411700001-
dc.identifier.issnl2405-8440-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats